Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -59K | 0 | 0 | 0 | 0 |
| Operating Income | -171M | -192M | -85M | -31M | -19M |
| EBITDA | -171M | -192M | -85M | -31M | -19M |
| Net Income | -155M | -178M | -72M | -30M | -19M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$25.61
-2.77% today
1Y Change
+75.93%
Window
Jun 26, 2025 → Jun 18, 2026
Coverage: 246 bars · Jun 26, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Mineralys Therapeutics, Inc. (MLYS) is a Healthcare stock with a market cap of $1.94B and listed on NASDAQ. The stock last traded around $25.61 and up 75.9% across the available one-year price window (Jun 26, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +37.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +37.4%, free cash flow +14.4% with operating margin 0.0% and ROIC -26.4%. Stock Foundry combines MLYS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MLYS
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MLYS Max Drawdown
-52.46%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for MLYS and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$19.4M
+34.9% YoY
Free Cash Flow
-$14.6M
+50.2% YoY
Revenue Growth
+0.0%
EPS Growth
+37.4%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -59K | 0 | 0 | 0 | 0 |
| Operating Income | -171M | -192M | -85M | -31M | -19M |
| EBITDA | -171M | -192M | -85M | -31M | -19M |
| Net Income | -155M | -178M | -72M | -30M | -19M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 173M | 114M | 49M | 88M | 11M |
| Total Assets | 662M | 206M | 252M | 114M | 11M |
| Total Liabilities | 15M | 15M | 10M | 167M | 34M |
| Shareholder Equity | 647M | 191M | 241M | -52M | -23M |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -173M | -114M | -49M | -88M | -11M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
15M
+50.2% YoY
Capital Expenditures
0
Free Cash Flow
15M
+50.2% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-32.9%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.